Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28048524 | 0.87 | MAPK1 (0.64) | MAPK1ALDH1A1SMN1; SMN2RAB9ACYP19A1 | |
| SCHEMBL9035635 | 0.84 | MAOA (0.68) | MAPK1ALDH1A1SMN1; SMN2RAB9AGPR132 | |
| SCHEMBL17541046 | 0.83 | TBXAS1 (0.48) | MAPK1KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL8010387 | 0.80 | TBXAS1 (0.67) | KDM4EALDH1A1SMN1; SMN2KMT2AGPR132 | |
| SCHEMBL8010384 | 0.80 | TBXAS1 (0.67) | KDM4EALDH1A1SMN1; SMN2KMT2AGPR132 | |
| SCHEMBL432927 | 0.80 | ALDH1A1 (0.57) | KDM4EALDH1A1SMN1; SMN2RAB9AKMT2A | |
| SCHEMBL158270 | 0.80 | RAB9A (0.68) | KDM4EALDH1A1SMN1; SMN2RAB9AMAPT | |
| SCHEMBL7311175 | 0.80 | MAPK1 (0.65) | MAPK1RAB9AKMT2AGPR132MEN1 | |
| SCHEMBL4060132 | 0.79 | MAPK1 (0.56) | MAPK1ALDH1A1SMN1; SMN2RAB9ACYP19A1 | |
| SCHEMBL3761776 | 0.79 | MAOB (0.62) | MAPK1SMN1; SMN2RAB9ACYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651413-B1 | NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES | PHARMAHUNGARY 2000 KFT (HU) | 2017-11-22 | — | — | EP | disclosed |
| EP-2651413-B1 | NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES | PHARMAHUNGARY 2000 KFT (HU) | 2017-11-22 | — | — | EP | disclosed |
| US-9487462-B2 | Inhibitors of matrix metalloproteinases | PHARMAHUNGARY 2000 KFT. (HU) | 2016-11-08 | — | — | US | disclosed |
| US-9487462-B2 | Inhibitors of matrix metalloproteinases | PHARMAHUNGARY 2000 KFT. (HU) | 2016-11-08 | — | — | US | disclosed |
| US-9487462-B2 | Inhibitors of matrix metalloproteinases | PHARMAHUNGARY 2000 KFT. (HU) | 2016-11-08 | — | — | US | disclosed |
| US-20130303572-A1 | NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES | TARGETEX KFT. (HU) | 2013-11-14 | — | — | US | disclosed |
| US-20130303572-A1 | NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES | TARGETEX KFT. (HU) | 2013-11-14 | — | — | US | disclosed |
| US-20130303572-A1 | NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES | TARGETEX KFT. (HU) | 2013-11-14 | — | — | US | disclosed |
| EP-2651413-A1 | NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES | Pharmahungary 2000 Kft. (HU) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080762-A1 | NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES | PHARMAHUNGARY 2000 KFT. (HU) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080762-A1 | NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES | PHARMAHUNGARY 2000 KFT. (HU) | 2012-06-21 | — | — | WO | disclosed |
| US-6300501-B1 | Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase | WARNER-LAMBERT COMPANY | 2001-10-09 | — | — | US | disclosed |
| EP-0938494-A1 | INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1997044350-A1 | INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1997-11-27 | — | — | WO | disclosed |
| EP-0365328-B1 | Pyridine derivatives | ZENECA LTD (GB) | 1996-04-03 | — | — | EP | disclosed |
| US-5053415-A | Antiischemic, antiinflammatory, antiarthritic agents, cardiovascular disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-10-01 | — | — | US | disclosed |
| EP-0365328-A2 | Pyridine derivatives | ZENECA LIMITED (GB) | 1990-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303572-A1 | NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES | TIMP3, MMP3, MMP13 | MAPK1 1944/4885KDM4E 2143/4885ALDH1A1 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.